A Retrospective and Prospective Multicenter Observational Study for the Evaluation of Incidence of Systemic Mastocytosis With Associated t(8;21) Acute Myeloid Leukemia in t(8;21) Acute Myeloid Leukemia
Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY
The observational study aimed at evaluating the incidence of systemic mastocytosis associated with t(8;21) AML in patients with de novo t(8;21) AML and their responses to first induction, and the prognosis from standard therapy.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 5
Healthy Volunteers: f
View:
• Male or female, Age (years) \>= 5;
• Newly diagnosed as t(8;21) AML patients according to World Health Organization (WHO) classification;
• Patients who sign the informed consent must have the ability to understand and be willing to participate in the study and sign the informed consent.
Locations
Other Locations
China
The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology
RECRUITING
Suzhou
Contact Information
Primary
Suning Chen, professor
chensuning@sina.com
+86-13814881746
Time Frame
Start Date: 2022-09-01
Estimated Completion Date: 2024-08-31
Participants
Target number of participants: 200
Treatments
Systemic Mastocytosis with associated t(8;21) AML
SM and AML were diagnosed according to the 5th edition WHO classification criteria.
The t(8;21) AML without Systemic Mastocytosis
The t(8;21) AML patients do not have associated Systemic Mastocytosis according to the 5th edition WHO classification criteria and no AML1-ETO clone was detected in mast cells.
OSM (Oligo-mastocytic SM) with associated t(8;21) AML
The t(8;21) AML patients do not have associated Systemic Mastocytosis according to the 5th edition WHO classification criteria, but AML1-ETO clones were detected in mast cells.
Related Therapeutic Areas
Sponsors
Leads: The First Affiliated Hospital of Soochow University